137 related articles for article (PubMed ID: 36746159)
1. Advancing Reproductive Health through Policy-Engaged Research in Abortion Care.
Munro SB; Dunn S; Guilbert ER; Norman WV
Semin Reprod Med; 2022 Nov; 40(5-06):268-276. PubMed ID: 36746159
[TBL] [Abstract][Full Text] [Related]
2. Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of community pharmacists.
Zusman EZ; Munro S; Norman WV; Soon JA
BMJ Open; 2022 Oct; 12(10):e063370. PubMed ID: 36207038
[TBL] [Abstract][Full Text] [Related]
3. Pharmacists' experiences dispensing misoprostol and readiness to dispense mifepristone.
Ferketa M; Moore A; Klein-Barton J; Stulberg D; Hasselbacher L
J Am Pharm Assoc (2003); 2024; 64(1):245-252.e1. PubMed ID: 37913990
[TBL] [Abstract][Full Text] [Related]
4. Canadian Newspapers Support Mifepristone Medication Abortion to Improve Fulfillment of the AAAQ Right to Health Framework (2015-2019).
Kendall T; Sriram P; Parmar A; Norman WV
Womens Health Issues; 2023; 33(6):592-599. PubMed ID: 37407397
[TBL] [Abstract][Full Text] [Related]
5. Integrating mifepristone into primary care in Canada's capital: A multi-methods exploration of the Medical Abortion Access Project.
LaRoche KJ; Wylie A; Persaud M; Foster AM
Contraception; 2022 May; 109():37-42. PubMed ID: 35031301
[TBL] [Abstract][Full Text] [Related]
6. Experiences with misoprostol-only used for self-managed abortion and acquired from an online or retail pharmacy in the United States.
Johnson DM; Ramaswamy S; Gomperts R
Contraception; 2024 Mar; 131():110345. PubMed ID: 38049047
[TBL] [Abstract][Full Text] [Related]
7. Exploring Canadian women's knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients.
Vogel KI; LaRoche KJ; El-Haddad J; Chaumont A; Foster AM
Contraception; 2016 Aug; 94(2):137-42. PubMed ID: 27125893
[TBL] [Abstract][Full Text] [Related]
8. Provision of first-trimester medication abortion in 2019: Results from the Canadian abortion provider survey.
Ennis M; Renner R; Guilbert E; Norman WV; Pymar H; Kean L; Carson A; Martin-Misener R; Dunn S
Contraception; 2022 Sep; 113():19-25. PubMed ID: 35351448
[TBL] [Abstract][Full Text] [Related]
9. Assessing abortion coverage in nurse practitioner programs in Canada: a national survey of program directors.
Sheinfeld L; Arnott G; El-Haddad J; Foster AM
Contraception; 2016 Nov; 94(5):483-488. PubMed ID: 27374736
[TBL] [Abstract][Full Text] [Related]
10. "It gives you autonomy over your own choices": A qualitative study of Canadian abortion patients' experiences with mifepristone and misoprostol.
LaRoche KJ; Foster AM
Contraception; 2020 Jul; 102(1):61-65. PubMed ID: 32304768
[TBL] [Abstract][Full Text] [Related]
11. "I'll just deal with this on my own": a qualitative exploration of experiences with self-managed abortion in the United States.
Raifman S; Ralph L; Biggs MA; Grossman D
Reprod Health; 2021 May; 18(1):91. PubMed ID: 33947413
[TBL] [Abstract][Full Text] [Related]
12. Trends in medication abortion provision before and after the introduction of mifepristone: A study of the National Abortion Federation's Canadian member services.
Yalahow A; Doctoroff J; Mark A; Foster AM
Contraception; 2020 Aug; 102(2):119-121. PubMed ID: 32325077
[TBL] [Abstract][Full Text] [Related]
13. US clinicians' perspectives on how mifepristone regulations affect access to medication abortion and early pregnancy loss care in primary care.
Srinivasulu S; Yavari R; Brubaker L; Riker L; Prine L; Rubin SE
Contraception; 2021 Jul; 104(1):92-97. PubMed ID: 33910031
[TBL] [Abstract][Full Text] [Related]
14. Implementation of mifepristone medical abortion in Canada: pilot and feasibility testing of a survey to assess facilitators and barriers.
Devane C; Renner RM; Munro S; Guilbert É; Dunn S; Wagner MS; Norman WV
Pilot Feasibility Stud; 2019; 5():126. PubMed ID: 31720004
[TBL] [Abstract][Full Text] [Related]
15. First trimester medication abortion practice in the United States and Canada.
Jones HE; O'Connell White K; Norman WV; Guilbert E; Lichtenberg ES; Paul M
PLoS One; 2017; 12(10):e0186487. PubMed ID: 29023594
[TBL] [Abstract][Full Text] [Related]
16. Perspectives Among Canadian Physicians on Factors Influencing Implementation of Mifepristone Medical Abortion: A National Qualitative Study.
Munro S; Guilbert E; Wagner MS; Wilcox ES; Devane C; Dunn S; Brooks M; Soon JA; Mills M; Leduc-Robert G; Wahl K; Zannier E; Norman WV
Ann Fam Med; 2020 Sep; 18(5):413-421. PubMed ID: 32928757
[TBL] [Abstract][Full Text] [Related]
17. Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe.
Guengant JP; Bangou J; Elul B; Ellertson C
Contraception; 1999 Sep; 60(3):167-72. PubMed ID: 10640161
[TBL] [Abstract][Full Text] [Related]
18. Medication to Manage Abortion and Miscarriage.
Beaman J; Prifti C; Schwarz EB; Sobota M
J Gen Intern Med; 2020 Aug; 35(8):2398-2405. PubMed ID: 32410127
[TBL] [Abstract][Full Text] [Related]
19. Medication abortion: Potential for improved patient access through pharmacies.
Raifman S; Orlando M; Rafie S; Grossman D
J Am Pharm Assoc (2003); 2018; 58(4):377-381. PubMed ID: 29752204
[TBL] [Abstract][Full Text] [Related]
20. Leadership for success in transforming medical abortion policy in Canada.
Dineley B; Munro S; Norman WV
PLoS One; 2020; 15(1):e0227216. PubMed ID: 31914156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
